A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
ImmunoGenesis
Precision Biologics, Inc
Dana-Farber Cancer Institute
BioNTech SE
ImmunityBio, Inc.
BioNTech SE
ImmunityBio, Inc.
ImmunityBio, Inc.
ImmunityBio, Inc.
Abramson Cancer Center at Penn Medicine
OHSU Knight Cancer Institute
Indiana University
University of Texas Southwestern Medical Center
HonorHealth Research Institute
Washington University School of Medicine
Lumos Pharma
Celgene
The Cooper Health System
Cambridge University Hospitals NHS Foundation Trust
Eli Lilly and Company
Pfizer
Radiation Therapy Oncology Group
Western Regional Medical Center
Incyte Corporation
Western Regional Medical Center
Incyte Corporation
Verastem, Inc.
Georgetown University
University of Cincinnati